The past week was notable on both policy and infrastructure fronts, with the FDA formalizing a one-pivotal-trial default and emphasizing mechanistic, real-world, and model-based confirmative evidence, and Eli Lilly bringing online its in-house AI supercomputer in Indianapolis to support large-scale biology and chemistry models.
A newly launched U.S. bra…